All In Biotech

Drug Trial Radar · NCT02555683

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 894 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

894

Actual

Start

Dec 11, 2015

Primary completion

Oct 21, 2019

Study completion Nov 4, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations: * patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population) * patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).

Conditions

  • Asthma

Interventions

  • QAW039Drug

    QAW039 150 mg once daily

  • QAW039Drug

    QAW039 450 mg once daily

  • PlaceboDrug

    Placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils SubpopulationTime frame: Baseline, Week 52
  2. Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall PopulationTime frame: Baseline, Week 52

Locations

234 sites in 27 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Gilbert, Arizona

  • Novartis Investigative Site

    Litchfield Park, Arizona

  • Novartis Investigative Site

    Peoria, Arizona

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Hawaiian Gardens, California

  • Novartis Investigative Site

    Newport Beach, California

  • Novartis Investigative Site

    Redondo Beach, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    Torrance, California

  • Novartis Investigative Site

    Westminster, California

  • Novartis Investigative Site

    New Haven, Connecticut

  • Novartis Investigative Site

    Brandon, Florida

  • Novartis Investigative Site

    New Smyrna Beach, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Ormond Beach, Florida

  • Novartis Investigative Site

    Sebring, Florida

  • Novartis Investigative Site

    Winter Park, Florida

  • Novartis Investigative Site

    Gainesville, Georgia

  • Novartis Investigative Site

    Marietta, Georgia

  • Novartis Investigative Site

    Crowley, Louisiana

  • Novartis Investigative Site

    Zachary, Louisiana

  • Novartis Investigative Site

    Bangor, Maine

  • Novartis Investigative Site

    Gaithersburg, Maryland

  • Novartis Investigative Site

    White Marsh, Maryland

  • Novartis Investigative Site

    Livonia, Michigan

  • Novartis Investigative Site

    Ypsilanti, Michigan

  • Novartis Investigative Site

    Picayune, Mississippi

  • Novartis Investigative Site

    Bellevue, Nebraska

  • Novartis Investigative Site

    Lincoln, Nebraska

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Corning, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Gastonia, North Carolina

  • Novartis Investigative Site

    Monroe, North Carolina

  • Novartis Investigative Site

    New Bern, North Carolina

  • Novartis Investigative Site

    Whiteville, North Carolina

Showing 40 of 234 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.